Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | EBP | Q15125 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | PARG | Q86W56 | 7/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | MLNR | O43193 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | UBE2M | P61081 | 1/20 | 0.30 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567055 | 1.00 | CTSK (0.35) | CTSKTLR7EBPMGLLPARG | |
| SCHEMBL25373929 | 1.00 | CTSK (0.35) | CTSKTLR7EBPMGLLPARG | |
| SCHEMBL25369931 | 0.94 | EBP (0.38) | CTSKEBPOPRM1OPRL1PTGS1 | |
| SCHEMBL25372158 | 0.93 | CTSK (0.38) | CTSKOPRM1OPRL1 | |
| SCHEMBL25370615 | 0.87 | EBP (0.37) | EBPCNR2 | |
| SCHEMBL26066102 | 0.87 | MLNR (0.36) | CTSKTLR7EBPPARGMLNR | |
| SCHEMBL25370731 | 0.86 | KCNH2 (0.35) | CTSKOPRM1OPRL1 | |
| SCHEMBL25371573 | 0.86 | KCNH2 (0.35) | CTSKOPRM1OPRL1 | |
| SCHEMBL25373285 | 0.86 | KCNH2 (0.35) | CTSKOPRM1OPRL1 | |
| SCHEMBL25371433 | 0.85 | CTSK (0.37) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | CTSK 4031/4885TLR7 4820/4885EBP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.